Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
复制标题
DOI：
10.1080/21645515.2017.1334746
复制
发表时间：
2017-01-01
影响因子：
4.8
通讯作者：
Quemeneur, Eric
中科院分区：
文献类型：
--
作者：
Bendjama, Kaidre;Quemeneur, Eric
虽然在临床上成功引入免疫检查点阻断剂重新引起了人们对免疫疗法的兴趣，但基因组测序的进展正在为设计日益个性化的疫苗开辟新的可能性。现在可以在单个患者水平上现实地考虑药物的个性化。与上一代癌症疫苗不同，新抗原定向疫苗将靶向由获得性肿瘤基因组突变产生的真正特异性肿瘤抗原。这种新一代疫苗诱导的免疫应答不会产生自身耐受性，可能会提高疗效。尽管如此，只有当赞助商设法满足一些科学，技术，后勤和监管挑战时，这种新技术才能保持其承诺。特别是，制造商将不得不在几周内设计、制造并向患者交付新的药物级。在本文中，我们简要回顾了目前在翻译个性化疫苗方面所尝试的技术，并探讨了在下一波癌症疫苗中由改良的安卡拉牛痘病毒提供的可能性。
While interest in immunotherapies is renewed by the successful introduction of immune checkpoint blocking agent in the clinic, advances in genome sequencing are opening new possibilities in the design of increasingly personalized vaccines. Personalization of medicine can now be realistically contemplated at the single patient level. Unlike the previous generation of cancer vaccines, neoantigen directed vaccines would target truly specific tumor antigens resulting from acquired tumor genome mutations. Immune response induced by this next generation vaccine would not be subject to self-tolerance and will likely result to enhanced efficacy. Nevertheless, this new technologies can hold to their promises only if sponsors manage to meet several scientific, technical, logistical and regulatory challenges. In particular manufacturers will have to design, manufacture, and deliver to the patient a new pharmaceutical grade in a matters of weeks. In this paper, we briefly review current technologies currently tried at the translation of personalized vaccines and explore the possibilities offered by the Modified Vaccinia virus Ankara in this next wave of cancer vaccines.